Bromocriptine and domperidone in the treatment of Parkinson disease.
In a single-blind trial of therapy in 20 patients with idiopathic Parkinson disease, domperidone prevented nausea and vomiting induced by bromocriptine without diminishing beneficial central effects. Combination of the two drugs permitted rapid increase in bromocriptine dosage from 22.5 mg per day to 148 mg per day, with 71% mean clinical improvement over baseline score; continuing efficacy of the regimen was evident for a mean follow-up of 2 months.
D001562:Benzimidazoles / Q000008:administration & dosage*; D001971:Bromocriptine / Q000008:administration & dosage* / Q000009:adverse effects; D004294:Domperidone; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy
D001562:Benzimidazoles; D010880:Piperidines; D001971:Bromocriptine; D007980:Levodopa; D004294:Domperidone